Pharmaceutical Executive January 2017

January 2017 | Volume 37, Issue 1
Pharmaceutical Executive January 2017
Columns
Connected ecosystems will change the future of healthcare. William King outlines three key value drivers.
Rethinking views on limited-efficacy drug approvals may be in order, says Casey McDonald.
Health reform, pricing pressures will shape drug marketing and development in 2017.
The seven ways for pharmas to ensure successful execution of action steps following brand "war games."
It's time to take advantage of a nascent technology embrace taking hold among market insights professionals.
Features
There are question marks when trying to size up the trajectory of the global pharma industry in 2017. One certainty, however, will be change.
Belén Garijo, CEO of Merck KGaA, Darmstadt, Germany’s healthcare business, shares her approach in transforming a traditional pharma unit focused on small molecules for chronic disease to a high-tech specialty producer of immunotherapy drugs for rare cancers.
With soaring valuations of companies in the public and M&A markets now a distant memory, the challenge for industry will be choosing the right mix of M&A, licensing, and partnering, writes Peter Young.
Special Sponsored Section
By Pharmaceutical Executive Editors
The government’s focus on generics is making healthcare more accessible to the general population in the Philippines, resulting in bolstered growth for the pharmaceutical industry and stronger overall economic performance.
native1_300x100
lorem ipsum